Atlas Trials

Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment

Clinical trial NCT03868722 · RECRUITING

Trial details

NCT number
NCT03868722
Sponsor
Rigshospitalet, Denmark
Status
RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
CLL
Start date
2019-10-11
Primary completion
2029-07-31
Enrollment
212

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.